ERBB2 and breast cancer: In the study by Cocco et al.(Cocco et al. 2018), 6 BC patients with both HER2 amplification and mutation were administered with neratinib; 2 patients had significantly reduced tumor volume, which lasted for 10 months in 1 patient, and 4 patients achieved stabilization of the disease.